Latest Commercial Revenue News

Vulcan Energy has started commercial-scale production in Germany of VULSORB, the proprietary adsorbent at the centre of its planned direct lithium extraction process. The material will supply first-fill volumes for Project Lionheart, although lithium production remains targeted for the second half of 2028.

Epiminder has enrolled the 75th patient in its DETECT study, meeting its September target as the US site network expands to 21 centres. The company expects to reach 100 enrolments in November and remains focused on completing the 210-patient study by the end of the first half of calendar 2027.

ION Video has secured an oversubscribed $4.25 million placement to fund independent trials of its video technology, with directors and management committing a further $1.2 million subject to shareholder approval. The capital will be used to test whether ION’s architecture can deliver measurable technical and financial benefits in real operating environments.

OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Temple & Webster defied a tough consumer backdrop to post record FY26 revenue of A$665 million and is targeting a substantial 50-80% EBITDA increase in FY27 under new CEO Susie Sugden.

Brisbane Broncos expect a 33% increase in half-year net profit before tax to $11.57 million, driven by higher crowd attendance and merchandise sales despite reduced ARLC funding and rising costs.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Brisbane Broncos capped a landmark 2025 season with both NRL and NRLW premiership victories, driving a 20.5% revenue surge and a 36% profit increase. The club rewarded shareholders with increased dividends amid record crowds and expanded community programs.

NoviqTech (ASX: NVQ) advances its biochar carbon removal strategy with a key non-binding MoU covering 70% of credits from its Great Barrier Reef project, targeting 2026 commercial milestones.